Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1065 of 1339 results for 0

  1. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

  2. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

  3. Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

    Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.

  4. ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)

    NICE has developed a medtech innovation briefing (MIB) on ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment

  5. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .

  6. Physical activity and the environment (NG90)

    This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.

  7. KardiaMobile for detecting atrial fibrillation (MTG64)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

  8. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

  9. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

    Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

  10. Powered microdebrider turbinoplasty for inferior turbinate hypertrophy (IPG498)

    Evidence-based recommendations on powered microdebrider turbinoplasty for inferior turbinate hypertrophy. This involves cutting away some of the swollen membrane covering the turbinates.

  11. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (IPG545)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  12. Acute kidney injury (QS76)

    This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

  13. The OPTIMIZER smart system for managing heart failure (MIB186)

    NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure .

  14. Microwave ablation for atrial fibrillation in association with other cardiac surgery (IPG122)

    Evidence-based recommendations on microwave ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat produced from microwave energy to interrupt abnormal electrical signals.

  15. Radiofrequency tissue reduction for turbinate hypertrophy (IPG495)

    Evidence-based recommendations on radiofrequency tissue reduction for turbinate hypertrophy. This involves using radiofrequency energy to close blood vessels that can cause swelling and destroy excess tissue.